Guardant Health
GH
145.83
+0.24
+0.16%
Guardant Health
US · GH
#820 by market cap
Listed 2018
145.83
+0.24
+0.16%
Periodic snapshot; not a real-time feed.
· 2026-11-20 20:02
Recent news
-
Rating change
H.C. Wainwright Maintains GH Research(GHRS.US) With Buy Rating, Maintains Target Price $65Market Newswire · 2026/11/9
-
Rating change
Roth MKM Initiates Guardant Health(GH.US) With Buy Rating, Announces Target Price $200Market Newswire · 2026/10/23
-
Rating change
A Quick Look at Today's Ratings for Guardant Health(GH.US), With a Forecast Between $180 to $220Market Newswire · 2026/11/7
-
Rating change
J.P. Morgan Maintains Guardant Health(GH.US) With Buy Rating, Maintains Target Price $195Market Newswire · 2026/10/14
-
Company notice
HHRG-WB (HHRG BHD): Changes in Sub. S-hldr's Int (Section 138 of CA 2016) - GH CONSORTIUM SDN BHDBursa Malaysia · 2026/2/12
-
Guggenheim Maintains GH Research(GHRS.US) With Buy Rating, Raises Target Price to $46Market Newswire · 2026/11/18
-
Rating change
Bernstein Maintains Guardant Health(GH.US) With Buy Rating, Maintains Target Price $210Market Newswire · 2026/10/19
-
GH Research Is Maintained at Buy by HC Wainwright & Co.Dow Jones · 2026/11/17
-
Bernstein Maintains Guardant Health(GH.US) With Buy Rating, Cuts Target Price to $190Market Newswire · 2026/11/19
-
Company notice
GH Advanced Materials: Report on Status of Specific Securities, Etc. Owned by Executives and Major ShareholdersOPENDART · 2026/10/7
-
Company notice
GH Research | SC 13G/A: Statement of acquisition of beneficial ownership by individuals (Amendment)-RA Capital Management, L.P.(12.9%),Peter Kolchinsky(12.9%), etc.SEC · 2024/11/15
-
Rating change
RBC Capital Maintains GH Research(GHRS.US) With Buy Rating, Maintains Target Price $42Market Newswire · 2026/11/10
-
Rating change
Piper Sandler Maintains Guardant Health(GH.US) With Buy Rating, Cuts Target Price to $190Market Newswire · 2026/11/10
-
Company notice
HHRG-WB (HHRG BHD): Changes in Sub. S-hldr's Int (Section 138 of CA 2016) - GH CONSORTIUM SDN BHDBursa Malaysia · 2026/1/29
-
Rating change
Morgan Stanley Maintains Guardant Health(GH.US) With Buy Rating, Maintains Target Price $200Market Newswire · 2026/10/20
-
CCORF Maintains GH Research(GHRS.US) With Buy Rating, Maintains Target Price $39Market Newswire · 2026/11/16
-
Rating change
Barclays Maintains Guardant Health(GH.US) With Buy Rating, Maintains Target Price $220Market Newswire · 2026/11/6
-
Rating change
BTIG Maintains Guardant Health(GH.US) With Buy Rating, Raises Target Price to $210Market Newswire · 2026/10/27
-
Company notice
HHRG-WB (HHRG BHD): Changes in Sub. S-hldr's Int (Section 138 of CA 2016) - GH CONSORTIUM SDN BHDBursa Malaysia · 2026/5/19
-
H.C. Wainwright Maintains GH Research(GHRS.US) With Buy Rating, Cuts Target Price to $55Market Newswire · 2026/11/17
-
Rating change
Barclays Maintains Guardant Health(GH.US) With Buy Rating, Raises Target Price to $220Market Newswire · 2026/10/7
-
Rating change
Barclays Maintains Guardant Health(GH.US) With Buy Rating, Maintains Target Price $200Market Newswire · 2026/9/18
-
Rating change
Analysts Are Bullish on These Healthcare Stocks: NeurAxis, Inc. (NRXS), Guardant Health (GH)TipRanks · 2026/9/16
-
Rating change
Goldman Sachs Maintains Guardant Health(GH.US) With Buy Rating, Raises Target Price to $225Market Newswire · 2026/9/21
-
Rating change
Morgan Stanley Maintains Guardant Health(GH.US) With Buy Rating, Raises Target Price to $200Market Newswire · 2026/10/12
Headlines are aggregated automatically and are not independently verified or edited by our team.
Quote time 2026-11-20 20:02:17 · For reference only, not investment advice and not tailored to your situation.
Guardant Health discussion 0 comments